Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Lung Cancer

• Publication date

  2007-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.LUNGCAN.2006.10.021PMID 17141357
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633.

  2006cited by this paper
• Phase II Randomized Study Comparing the Toxicity Profile of Gemcitabine plus Cisplatin with Gemcitabine plus Oral Etoposide in the Treatment of Advanced Non-Small Cell Lung Cancer

  2005cited by this paper
• Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

  2005cited by this paper
• O-154 Impact of maintaining Hb with epoetin alfa on time toprogression (TTP), overall survival (OS), quality of life (QOL) and transfusion reduction in limited disease SCLC patients

  2005cited by this paper
• Adjuvant chemotherapy for non-small-cell lung cancer--the smoke clears.

  2005cited by this paper
• Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.

  2005cited by this paper
• I don't underdose my patients...do I?

  2005cited by this paper
• Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials

  2005cited by this paper
• Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

  2005cited by this paper
• Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.

  2005cited by this paper
• Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers.

  2005cited by this paper
• ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association

  2005cited by this paper
• P-779 Impact of anemia on outcomes of therapy in limited small celllung cancer (L-SCLC): An analysis of studies performed by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)

  2005cited by this paper
• Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633.

  2004cited by this paper
• Role of epoetin in the management of anaemia in patients with lung cancer.

  2004cited by this paper
• Correlation between perioperative blood transfusion and prognosis of patients subjected to surgery for stage I lung cancer.

  2003cited by this paper
• Breast cancer trial with erythropoietin terminated unexpectedly.

  2003cited by this paper
• Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.

  2003cited by this paper
• Management of anemia in patients receiving chemotherapy.

  2002cited by this paper
• Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

  2002cited by this paper
• Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

  2002cited by this paper
• Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review.

  2001cited by this paper
• Anemia as an independent prognostic factor for survival in patients with cancer

  2001cited by this paper
• Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer.

  2001cited by this paper
• A phase II trial of vinorelbine and cisplatin in previously untreated inoperable non--small-cell lung cancer.

  2000cited by this paper
• Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study.

  1999cited by this paper
• The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix

  1999cited by this paper
• Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.

  1998cited by this paper
• Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study.

  1997cited by this paper
• Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.

  1997cited by this paper
• Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.

  1997cited by this paper
• Paclitaxel and cisplatin in patients with non-small cell lung cancer: results of a phase II trial.

  1996cited by this paper
• Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer

  1996cited by this paper
• Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group.

  1996cited by this paper
• Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC).

  1995cited by this paper
• Chemotherapy-induced anemia in patients with primary lung cancer.

  1992cited by this paper
• The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma.

  1992cited by this paper
• Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.

  1991cited by this paper

• Trends in hemoglobin-to- red cell distribution width ratio and its prognostic value for all-cause, cancer, and cardiovascular mortality: a nationwide cohort study

  2025cites this paper
• Human Ductal Carcinoma In Situ: Advances and Future Perspectives.

  2023cites this paper
• A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer

  2023cites this paper
• Relationship between the Hemoglobin-to-Red Cell Distribution Width Ratio and All-Cause Mortality in Septic Patients with Atrial Fibrillation: Based on Propensity Score Matching Method

  2022cites this paper
• Baseline anemia and anemia grade are independent prognostic factors for stage IV non-small cell lung cancer

  2021cites this paper
• Preoperative hemoglobin-to-red cell distribution width ratio as a prognostic factor in pulmonary large cell neuroendocrine carcinoma: a retrospective cohort study

  2021cites this paper
• The predictive value of pretreatment haemoglobin-to-red cell distribution width ratio for overall survival of patients with advanced non-small cell lung cancer: a propensity score matching analysis

  2021cites this paper
• Development of a Survival Prognostic Model for Non-small Cell Lung Cancer

  2020cites this paper
• KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma

  2020cites this paper
• Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT)

  2019cites this paper
• A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width

  2019cites this paper
• Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin

  2019cites this paper
• Adjuvant Therapy in Patients With Completely Resected Non–small‐cell Lung Cancer: Current Status and Perspectives

  2019cites this paper
• Prognostic Value of Ferritin-to-Hemoglobin Ratio in Patients with Advanced Non-Small-Cell Lung Cancer

  2019cites this paper
• Preoperative anemia as a prognostic factor in patients with lung cancer: a systematic review and meta-analysis of epidemiological studies

  2019influential citation
• The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis

  2018cites this paper
• Pretreatment Hemoglobin Level Is an Independent Prognostic Factor in Patients with Lung Adenocarcinoma

  2018cites this paper
• Pre-treatment hemoglobin levels are an independent prognostic factor in patients with non-small cell lung cancer.

  2018cites this paper
• Is there any correlation between pretreatment haemoglobin levels and prognosis of patients with non-small-cell lung cancer?

  2018cites this paper
• Reply to Suciu et al.

  2018cites this paper
• Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.

  2017cites this paper
• Prognostic Significance of Host-related Biomarkers for Survival in Patients with Advanced Non-Small Cell Lung Cancer

  2017cites this paper
• Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.

  2014cites this paper
• Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

  2013cites this paper
• Adjuvant Chemotherapy of Non-Small Cell Lung Cancer

  2012cites this paper
• The association between RhEPO and FN expression in glomerular mesangial cells.

  2012cites this paper
• Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials.

  2011cites this paper
• Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations

  2011cites this paper
• 可手术的非小细胞肺癌患者贫血的发生和预后的生存分析

  2010cites this paper
• Anemia asociada al cáncer de pulmón: ¿factor pronóstico, predictivo, ambos o ninguno?

  2008cites this paper
• [Impact of hemoglobin level on lung cancer survival].

  2008cites this paper
• Efecto del valor de la hemoglobina en la supervivencia del cáncer de pulmón

  2008cites this paper
• [Lung cancer related anemia: prognosis factor, predictive, both or none?].

  2008cites this paper